Current available jobs worldwide.
Join our team
News and Features
7-10-2015: U.S. FDA Approves Otsuka and Lundbeck’s REXULTI® (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
6-22-2015: Survey Results Imply Adults with Schizophrenia, Caregivers Frustrated by Tradeoffs in Managing Symptoms and Medication Side Effects
Progress in Mind
Lundbeck is dedicated to raising awareness and research into brain diseases.